Cosmos Health Provides Update on United States Business; Q4 2026 U.S. Revenue Expected to Reach $15 Million, with Gross Profit of $10.5 Million; Active U.S.…
Cosmos Health Inc. (COSM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Cosmos Health Provides Update on United States Business; Q4 2026 U.S. Revenue Expected to Reach $15 Million, with Gross Profit of $10.5 Million; Active U.S. Subscriptions Up 42% from 6,287 to 8,940 in Just Five Days · Q4 2026 U.S. revenue: approximately $15 million e
How this was made
The 30-second read
Why it matters
The updated guidance reflects accelerated subscription adoption and higher gross margins, which may attract short‑term buying interest.
Market read
Guidance update is a primary corporate disclosure that could move the stock modestly.
What to watch
Potential supply‑chain constraints or regulatory hurdles could temper growth.
Cosmos Health Provides Update on United States Business; Q4 2026 U.S. Revenue Expected to Reach $15 Million, with Gross Profit of $10.5 Million
The filing presents a sizable forward outlook for the U.S. direct-to-consumer business and rapid five-day growth in platform activity, but it does not report completed-quarter financial results and states that the subscription and order figures are preliminary and unaudited.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| U.S. online checkout orders tracked as of October 19, 2026other | 14,624 | up 34% | – |
| Active U.S. subscriptions as of October 19, 2026other | 8,940 | up 42% | – |
| Monthly subscription value at standard renewal pricing as of October 19, 2026other | $1,325,338 | up 44% | – |
| U.S. online checkout orders including a subscription since inception of the subscription platformother | 65.2% | – | – |
| Average product units per subscriptionother | approximately 2.4 product units per subscription | – | – |
fourth quarter ending December 31, 2026 outlook
- Revenueapproximately $15 million
- Gross marginapproximately 70%
- NoteU.S. gross profit: approximately $10.5 million
- NoteFirst orders from new subscribers: ~$8.2 million
- NoteRenewals of subscriptions started during the quarter: ~$3.3 million
- NoteTotal subscription revenue: ~$11.5 million
- NoteOne-time purchases: ~$3.5 million
- NoteDecember expected to be the strongest month
- NoteU.S. daily sales: from $60,000 at its start to more than $200,000 by year-end
- NoteActive U.S. subscriptions: more than 40,000 expected by year-end
What drove it
- Increased marketing investment in the U.S. direct-to-consumer platform
- Expanded digital customer acquisition
- Rising brand awareness
- A broadening product offering
- Growing repeat purchases
- Strong subscription adoption at checkout
- New subscription cohorts are expected to renew and add to the recurring revenue base.
Concerns
- The fourth quarter 2026 U.S. outlook is based on the Company's current growth trajectory and internal assumptions.
- Subscription and order figures are preliminary and unaudited and may differ from amounts reported in the Company's financial statements.
- Monthly subscription value is calculated at standard renewal pricing, is an operating metric, is not a measure of revenue under U.S. GAAP and does not represent revenue earned to date.
- The outlook reflects a significantly expanded marketing budget for the fourth quarter.
What to watch
- Conversion of tracked checkout orders and active subscriptions into reported U.S. revenue.
- Whether renewals build month after month as successive subscriber cohorts renew.
- Progress toward more than 40,000 active U.S. subscriptions by year-end.
- Whether daily U.S. sales exceed $200,000 by year-end.
- Realization of the expected approximately 70% gross margin.
Analysis
This filing is a forward-looking U.S. business update rather than a release of completed-quarter financial results. Cosmos Health expects approximately $15 million of U.S. revenue and approximately $10.5 million of U.S. gross profit for the fourth quarter ending December 31, 2026, at an expected gross margin of approximately 70%. The outlook applies to the U.S. online direct-to-consumer business and is supported by a significantly expanded marketing budget.
Management, verbatim
Our U.S. business has strong momentum entering the fourth quarter, and it is building further. In the five days since our last update, active subscriptions grew 42% to 8,940 and their monthly value rose 44% to more than $1.3 million, which reinforces our confidence in the outlook. We expect approximately $15 million in U.S. revenue and $10.5 million in gross profit for the quarter, with daily sales exceeding $200,000 and more than 40,000 active subscriptions by year-end.
Greg Siokas, CEO of Cosmos Health
What matters most to us is the quality of that revenue. Every month, a new cohort of subscribers renews and adds to a recurring revenue base, at strong margins. We look forward to keeping investors updated on our progress in the weeks ahead.
Greg Siokas, CEO of Cosmos Health
Not in the filing
stated, not guessed- Completed-quarter total revenue
- Completed-quarter segment revenue
- GAAP gross profit and gross margin
- GAAP operating income or loss
- Non-GAAP operating income or loss
- GAAP net income or loss
- Non-GAAP net income or loss
- GAAP earnings or loss per share
- Non-GAAP earnings or loss per share
- Operating cash flow
- Free cash flow
- Cash and cash equivalents
- Debt
- Share repurchases
- Dividends
- Operating-expense guidance
- Tax-rate guidance
- Previous outlook for comparison
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Cosmos Health is a diversified healthcare group with a direct‑to‑consumer subscription model.
Ticker impact
Cosmos Health filed an 8‑K providing updated Q4 2026 U.S. revenue guidance of $15 M and gross profit of $10.5 M.
likely upward pressure as investors price in stronger U.S. sales outlook
The company disclosed fresh guidance that exceeds prior expectations, indicating accelerating subscription growth and higher margins.
Market effects
May boost sentiment for niche health‑tech and subscription‑based consumer health firms.
Limited to U.S. consumer health segment; negligible broader regional effect.
Minimal global impact beyond niche investors.
Counterpoint
Guidance could be overly optimistic given the short‑term nature of subscription spikes.
Key entities
- ExecutiveGreg Siokas
CEO of Cosmos Health who provided the guidance.
